0728. Removal of natural anti-galactose α1,3 galactose antibodies with GAS914 enhances humoral immunity and prevents sepsis mortality in mice by R Manez et al.
POSTER PRESENTATION Open Access
0728. Removal of natural anti-galactose a1,3
galactose antibodies with GAS914 enhances
humoral immunity and prevents sepsis mortality
in mice
R Manez1,2*, M Perez-Cruz2, D Bello2, MA Dominguez3, C Costa2
From ESICM LIVES 2014
Barcelona, Spain. 27 September - 1 October 2014
Introduction
Increasing numbers of patients with immunodeficiencies,
malignant diseases, advanced surgeries and prolonged
stays in intensive care units are at risk for developing
infections by enteric bacteria, which often are systemic
(sepsis) and caused by multidrug resistance isolates.
Intestinal bacteria provide also a constant antigenic sti-
mulation for the synthesis of natural anti-carbohydrate
antibodies such as those targeting blood group-associated
antigens or galactose a1,3 galactose (Gal). Enteric bac-
teria that cause sepsis are more likely to bind anti-Gal
antibodies than those isolated from stools, which appears
related to the higher resistance to serum killing evi-
denced by the former microorganisms.
Objective
Investigate the impact of removing anti-Gal antibodies
in the sepsis after cecal ligation and puncture (CLP) in
a1,3 galactosyltransferase knockout (Gal-KO) mice.
These mice produce from four months of age natural
anti-Gal antibodies as humans without the need of any
additional Gal antigen exposure.
Methods
Anti-Gal antibodies were removed in vivo using a solu-
ble Gal trisaccharide-polylysine conjugate (GAS914) and
determined by ELISA. Binding of serum antibodies to
Escherichia Coli isolated from Gal-KO mice blood was
performed by FACS and serum bactericidal activity was
determined by a complement-mediated assay. The
pattern of 40 cytokines and antibodies against 577 car-
bohydrate and bacterial antigens before and after
GAS914 was evaluated by two different arrays.
Results
GAS914 at 10 mg/kg subcutaneously every other day for
two weeks led to the removal of anti-Gal antibodies in
Gal-KO mice from day one. Removal of anti-Gal antibo-
dies with GAS914 significantly improved survival in Gal-
KO mice subsequently subjected to CLP on day 3 (83%
versus 35% in controls; p< 0.01). On day one after CLP
there was a reduction of 50% in the level of anti-Gal anti-
bodies in untreated Gal-KO mice. Blood cultures
obtained 24 h after CLP were positive for Escherichia
Coli in 83% of mice carrying anti-Gal antibodies and
87.5% of the animals lacking them. Pulse field electro-
phoresis did not show differences between E. Coli blood
isolates from GAS914-treated and untreated mice.
Removal of anti-Gal antibodies was associated with a sig-
nificant increase in serum IgG binding and bactericidal
activity to E. Coli. GAS914 administration was associated
in the glycan array with the removal of anti-Gal antibo-
dies and the significant augment of binding to several
bacterial antigens. Finally, GAS914 also significantly
reduced the level of several proinflammatory and anti-
inflammatory cytokines prior to CLP in Gal-KO mice.
Conclusion
Removal of natural anti-Gal antibodies with GAS914
enhances humoral immunity against enteric bacteria
expressing Gal-antigen isolated from the blood prevent-
ing sepsis mortality after CLP in mice. Depletion of
existing antibodies may be a new approach to boost
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immunity and prevent or treat infection diseases and
other disorders.
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